You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

7 search results for: endotype

ERS-ISIAN 2023 | From <b>Endotype</b> to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

expert video

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

9 min

Rhinology

Prof. Peter Hellings discusses the interconnection between the pathophysiology, burden and clinical management of uncontrolled and/or severe CRSwNP

From <b>Endotype</b> to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

expert video

From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

9 min

Rhinology

Prof. Peter Hellings discusses the interconnection between the pathophysiology, burden and clinical management of uncontrolled and/or severe CRSwNP.

expert video

Importance of Endotyping in CRSwNP

2 min

Rhinology

Prof. Wytske Fokkens discusses the role of endotyping in the management of CRSwNP.

expert video

Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis - Q&As

11 min

Dermatology

Expert insights on the plasticity of inflammation, atopic dermatitis endotypes, and dysbiosis – Audience Q&A from the ADVENT symposium at ISID 2023.

expert video

Defining Mechanisms of Anosmia in CRSwNP

2 min

Rhinology

Prof. Wytske Fokkens examines what is known and what else should be explored to understand the mechanisms of anosmia in patients with CRSwNP.

expert video

CRSwNP: A Chronic Type 2 Inflammatory Disease

2 min

Rhinology

Prof. Peter Hellings describes how type 2 inflammation drives CRSwNP.

expert video

ATS 2024 | Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?

42 min

Pulmonology

Join leading experts for an educational symposium where they delve into the clinical consequences and real-world patient burden of type 2 inflammation in asthma and COPD.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: TaiwanChange country/region